This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Arbutus, Genevant Sciences escalate Moderna patent feud with global campaign

( March 5, 2025, 14:46 GMT | Official Statement) -- MLex Summary: In a series of complaints filed in Canada, Japan, Switzerland and at the Unified Patent Court, Arbutus Biopharma and Genevant Sciences are kicking their patent enforcement campaign against Moderna into high gear.  The parties were already proceeding to trial in the US District Court for the District of Delaware later this year on allegations Moderna infringes US Patent Nos. 11,141,378, 8,058,069, 8,429,359, 8,822,668, 9,364,435, and 9,504,651. Now, Arbutus and Genevant say they are seeking damages and injunctive relief globally against Moderna over lipid nanoparticle technology implicated by not only Moderna's Spikevax Covid-19 vaccine, but also potentially its RSV vaccine mRESVIA. See attached document....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections